top of page
  • Writer's pictureEva Stahl

Mecuris discontinues its services at the end of the year

We regret to announce today that we have to discontinue the services of the Mecuris Solution Platform at the end of 2023. The Mecuris team would like to express its gratitude to everyone who has accompanied us on our journey, believed in us and supported us.

A look back and a heartfelt thank you

Since Mecuris was founded in 2016, we have pursued a common vision: to support clinicians worldwide in improving the efficiency and quality of individualized care for users and patients through customized and additively / hybrid manufactured orthoses and prostheses.

Mecuris has achieved considerable achievements and milestones along the way. We proudly announced the launch of the first CE-marked 3D-printed prosthetic foot in 2018. We were especially proud of the development of the functional, 3D-printed children's prosthetic foot FirStep. Additively manufactured prosthetic covers and orthoses as well as the establishment of the digital lab - the Mecuris Solution Platform - were key elements of Mecuris.

Since mid-2021, we have focused exclusively on expanding and optimizing our digital services on the web-based Mecuris Solution Platform. Although this was a major change for Mecuris, it allowed us to concentrate fully on the requirements of the market.

Since its founding, Mecuris has played a leading role in the digitalization of orthopaedic technology with its innovative ideas. We have been part of numerous research projects, have always been a welcome guest at conferences and our publications have attracted a great deal of interest.

Despite these successes and innovative achievements, Mecuris was unable to reach economic viability for various reasons. Although the technology and patents behind our products will live on, we will discontinue the Mecuris Solution Platform services on December 31, 2023.

We look back on an inspiring journey in digital orthopaedic technology. We would like to thank all our customers, partners and investors for their cooperation, support and belief in us.

We fought as a team until the very end and continue to believe in the potential of digitalization in orthopaedic technology. We therefore hope that we will see some of you again. As our colleague Richard always says so beautifully: "Keep creating!"

With this in mind, we would like to thank you once again and wish you all the best on your journey in the digitalization of orthopaedic technology.


bottom of page